The stock rose 3.1 per cent to 67 cents and is up 124 per cent this year, having spiked to a 1 1/2-year high in July after giving guidance on its expected first half.
While Serko had warned the second half of the year is typically weaker, Grafton said the company said it still expects trading revenue to be between 25 per cent and 30 per cent ahead of the previous second half.
In 2014, the company raised $17m selling shares at $1.10 apiece and existing investors sold a further $5m into the offer, however, the stock has been punished as a slowing Australian economy and late product launches weighed on Serko's revenue. Serko then raised $8.1m from institutional and existing investors at 84 cents apiece in late 2015, having previously signalled it didn't plan to go back to the market after its June 2014 initial public offering.
In March it said its existing Callaghan Innovation grant has been extended for a further two years, to June 30, 2019, with an additional value of $2m. The new funding is an extension to a previous $4.2m Callaghan Innovation research and development growth grant. The additional funding is being used to develop predictive technology, it said.
(BusinessDesk receives assistance from Callaghan Innovation to cover the commercialisation of innovation.)